NIH urges dilated eye exams to detect glaucoma

The National Eye Institute (NEI), a part of the National Institutes of Health, observes Glaucoma Awareness Month each January by encouraging Americans at higher risk for glaucoma to schedule a comprehensive dilated eye exam and to make a habit of doing so every one to two years. While anyone can get glaucoma, people at higher risk include African Americans age 40 and over; adults over the age of 60, especially those who are Mexican American; and people who have a family history of the disease.

is a major cause of vision loss in the United States and it is becoming more prevalent as our population ages. About 2.7 million Americans 40 and older have primary open-angle glaucoma, the most common form, and this number is expected to grow. Several large studies have shown that eye pressure is a major risk factor for . In open-angle glaucoma pressure inside the eye rises to a level that may damage the optic nerve. When the optic nerve is damaged from increased pressure, vision loss may result. "Vision Problems in the U.S.," a report released in 2012, by Prevent Blindness America and NEI, predicts that by 2030 the disease will affect 4.2 million Americans.

Glaucoma can be detected in its early stages through a comprehensive dilated before vision loss occurs. During this exam, drops are placed in the eyes to dilate, or widen, the pupils. This allows an eye care professional to examine the optic nerve for signs of damage and other possible problems. An eye pressure test alone is not enough to detect glaucoma. People in the higher risk categories should not wait until they notice a problem with their vision to have an eye exam. Primary open-angle glaucoma often has no symptoms in its early stages, so people may not know they have glaucoma until they start to have noticeable vision loss.

NEI leads the nation's vision research efforts and is committed to finding better prevention, detection, and treatment of eye diseases and disorders. In 2012, NEI invested $71 million in a wide range of studies to understand causes and potential areas of treatment for glaucoma.

The broad scope of NEI-funded glaucoma research ranges from gene therapy to stem cells, drug treatments, vaccines to protect the optic nerve cells, advanced imaging tools to view the retina and optic nerve, and new techniques to study glaucoma disease mechanisms, such as new mouse models that simulate glaucoma. These models enable scientists to study how increased causes optic nerve cell death. For more information about glaucoma research programs at NEI, visit http://www.nei.nih.gov .

add to favorites email to friend print save as pdf

Related Stories

Open-angle glaucoma up 22 percent in last 10 years

Jan 01, 2013

(HealthDay)—The prevalence of open-angle glaucoma has increased more than 20 percent in the last 10 years and currently affects more than 2.7 million Americans age 40 years and older, according to a report ...

Researchers identify an early predictor for glaucoma

Jan 02, 2013

A new study finds that certain changes in blood vessels in the eye's retina can be an early warning that a person is at increased risk for glaucoma, an eye disease that slowly robs people of their peripheral vision. Using ...

Recommended for you

Training can improve visual field losses from glaucoma

Apr 17, 2014

(HealthDay)—Visual field loss from glaucoma is in part reversible by behavioral, computer-based, online controlled vision training, according to a study published in the April issue of JAMA Ophthalmology.

Fewer ophthalmologists equals less diabetic eye care

Apr 15, 2014

(HealthDay)—In areas with less access to ophthalmologists, fewer individuals with diabetes, diabetic retinopathy, and age-related macular degeneration (ARMD) receive care, according to a study published ...

User comments